Compare ProShares Ultra Silver ETF (AGQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Merck & Co., Inc. — how do they compare? ProShares Ultra Silver ETF trades at $64.87, while Merck & Co., Inc. trades at $125.35 (market cap $318.26B). The key difference: Merck & Co., Inc. pays a 2.64% dividend while ProShares Ultra Silver ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | MRK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $129.52 |
52-Week Low | $48.15 | $77.60 |
Market Cap | — | $318.26B |
Enterprise Value | — | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
Merck (MRK) trades at $126.78, showing stable recent performance with strong institutional interest. The company demonstrates solid fundamentals with 2025 revenue of $65.01B and net income of $18.25B, representing a 28.07% profit margin. Recent earnings have consistently beaten expectations, and the company is actively expanding through strategic acquisitions like Terns Pharmaceuticals. Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators suggest some consolidation may be needed.
Merck presents a compelling investment case with strong profitability, consistent earnings beats, and strategic pipeline expansion through M&A. The stock offers 9.9% upside to the consensus price target of $139.33, supported by 67.6% analyst buy ratings. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The company's robust cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
